Ferring and IMAB Ink Contract for Potential IBD Therapy Olamkicept in Asia
News
Ferring Pharmaceuticals and Shangai-based biotech IMAB signed a licensing agreement granting IMAB exclusive rights to olamkicept (pINN), a potential drug for inflammatory bowel disease (IBD), in Asia. Under the terms of ... Read more